# Bendamustine and Rituximab Alternating With Cytarabine and Rituximab for Untreated Mantle Cell Lymphoma

> **NCT02728531** · PHASE1 · COMPLETED · sponsor: **Washington University School of Medicine** · enrollment: 18 (actual)

## Conditions studied

- Mantle Cell Lymphoma

## Interventions

- **DRUG:** Bendamustine
- **DRUG:** Rituximab
- **DRUG:** Cytarabine
- **DRUG:** Pegfilgrastim
- **PROCEDURE:** Leukapheresis
- **DRUG:** Filgrastim
- **PROCEDURE:** Autologous stem cell transplant

## Key facts

- **NCT ID:** NCT02728531
- **Lead sponsor:** Washington University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-04-18
- **Primary completion:** 2019-01-16
- **Final completion:** 2023-08-16
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2023-11-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02728531

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02728531, "Bendamustine and Rituximab Alternating With Cytarabine and Rituximab for Untreated Mantle Cell Lymphoma". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02728531. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*